Author:

Janknegt R

Hospital Pharmacist, Orbis Medisch Centrum, The Netherlands

Source:

Journal of Pharmaceutical Care & Health Systems

Abstract
 

The treatment of plaque psoriasis is changing because of the introduction of new treatment options. The goal of this article is to allow a transparent and rational choice of medicines by means of the System of Objectified Judgement Analysis. The following selection criteria (relative weight) were applied: approved indications (40), drug interactions (60), clinical efficacy (400), safety (300), dosage frequency (100) and documentation (100). Acquisition cost was not taken into consideration to allow a preselection on quality aspects only. Adalimumab, etanercept, infliximab and ustekinumab were compared on these criteria. Infliximab and ustekinumab showed the highest scores and are the most suitable medicines for the treatment of severe plaque psoriasis. Of course, the cost will play a key role in the final selection in individual hospitals.

Keywords:

Approved indications; Drug interactions; Clinical efficacy; Safety; Dosage frequency

Read the whole article in the PDF file BELOW

Copyright:

© 2014 Janknegt R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.